ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
113.89
+6.47 (+6.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close107.42
Open113.80
Bid113.30 x 800
Ask114.42 x 1200
Day's Range109.59 - 114.79
52 Week Range92.56 - 141.86
Volume3799877
Avg. Volume1,799,506
Market Cap25B
Beta (3Y Monthly)1.67
PE Ratio (TTM)17.46
EPS (TTM)6.52
Earnings DateFeb 3, 2020 - Feb 7, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est149.45
  • An Activist Investor Pushed This Biotech To Sell — Why It Refused
    Investor's Business Daily

    An Activist Investor Pushed This Biotech To Sell — Why It Refused

    Alexion Pharmaceuticals decided against selling itself, the biotech company said in a news release on Friday — prodding ALXN stock to jump. An activist investor suggested it launch a sale.

  • Barrons.com

    The Dow Is Up 336 Points Because the Jobs Report Was Just That Good

    The Dow Jones Industrial Average gained 1.2% on a strong November employment report, while the S&P 500 and the Nasdaq Composite were both trading up 1.0%.

  • MarketWatch

    Alexion stocks rises on decision not to consider a sale

    Shares of Alexion Pharmaceuticals are up 6% in morning trading after the company halted its stock in premarket trading to announce that it would not consider a sale, as recommended by Elliott Management. The biopharmaceutical company said its board had unanimously decided not to pursue a sale and that it had not received any offers. "We do not believe this approach is the best path for driving shareholder value," the company said in a statement. Alexion markets several drugs, including Soliris, a treatment for a number of rare diseases that costs $500,000 a year. Shares of Alexion have gained 10% year-to-date, compared to the S&P 500 , which is up 24%.

  • Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
    Zacks

    Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

    Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

  • Reuters

    UPDATE 3-Alexion Pharma rejects Elliott's push for "proactive sale"

    Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously rejected hedge fund Elliott Management's push for a "proactive sale" process of the entire company because it would not be in the best interest of shareholders. Alexion has been fighting to maintain its leadership in treating certain rare blood disorders, and has embarked on a string of acquisitions to boost its pipeline of rare disease drugs. In October, it agreed to buy rival Achillion Pharmaceuticals Inc for about $930 million.

  • Business Wire

    Alexion Issues Statement on Path to Value Creation

    Alexion Issues Statement on Path to Value Creation

  • Barrons.com

    The Dow Goes Negative Despite a Glimmer of Hope on Trade

    STOCKSTOWATCHTODAY BLOG Reversal. The three major U.S. stock mark indexes slipped into negative territory after beginning the day in the green amid continued optimism about trade. Near midday, the Dow Jones Industrial Average was down 33 points, or 0.

  • 5 Discounted PEG Stocks for GARP Investors
    Zacks

    5 Discounted PEG Stocks for GARP Investors

    Although PEG is categorized under value investing, it follows the principles of both growth and value investing.

  • Adopt Rising P/E Technique With These 5 Top-Ranked Stocks
    Zacks

    Adopt Rising P/E Technique With These 5 Top-Ranked Stocks

    What bargain hunting? Stocks with a rising P/E can also be worth buying too.

  • ALXN vs. ILMN: Which Stock Is the Better Value Option?
    Zacks

    ALXN vs. ILMN: Which Stock Is the Better Value Option?

    ALXN vs. ILMN: Which Stock Is the Better Value Option?

  • 8 Stocks Paul Tudor Jones Continues To Buy
    GuruFocus.com

    8 Stocks Paul Tudor Jones Continues To Buy

    Alphabet on the list. Continue reading...

  • Hedge Funds Are Getting Crazy About Alexion Pharmaceuticals, Inc. (ALXN)
    Insider Monkey

    Hedge Funds Are Getting Crazy About Alexion Pharmaceuticals, Inc. (ALXN)

    Is Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]

  • Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More
    Zacks

    Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

    Key highlights of the past week include regulatory and pipeline updates.

  • The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
    Zacks

    The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

    The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

  • Business Wire

    Alexion to Present at the 2019 Evercore ISI HealthCONx

    Alexion Pharmaceuticals today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET.

  • 4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal
    Zacks

    4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal

    Here are four stocks that boast promising prospects and are most likely to be takeout targets.

  • Billionaire Ray Dalio Snaps Up These 3 “Strong Buy” Stocks
    TipRanks

    Billionaire Ray Dalio Snaps Up These 3 “Strong Buy” Stocks

    When billionaire financier Ray Dalio makes a move, Wall Street pays attention. Dalio, who got his start working on the floor of the New York Stock Exchange trading commodity futures, founded the world’s largest hedge fund, Bridgewater Associates, in 1975. With the firm managing about $150 billion in global investments and Dalio’s own net worth coming at $18.7 billion, he has earned guru-like status by taking the opinions of experts that disagreed with him into consideration.“I learned a great fear of being wrong that shifted my mind-set from thinking ‘I’m right’ to asking myself ‘How do I know I’m right?’ And I saw clearly that the best way to answer this question is by finding other independent thinkers who are on the same mission as me and who see things differently from me,” he wrote in his book Principles.On Friday, the Wall Street Journal reported that Bridgewater made a more than $1 billion bet that the market would drop in the next few months. However, Dalio took to Twitter to deny this, claiming that the firm has no such bet. Against this backdrop, investors want to know if the fund manager is simply hedging the portfolio, or if the firm is really as bearish as the report made it out to be.Looking into Bridgewater's basket of stocks, we’ve chosen three of the fund’s new holdings that TipRanks’ Stock Screener reveals as "strong buys" and offer healthy upside potential. Let's take a closer look and see what Wall Street analysts have to say.Cleveland-Cliffs (CLF)Formerly known as Cliffs Natural Resources, Cleveland-Cliffs is one of the top iron ore mining companies and operators. Not only is it the largest iron ore producer of pellets in North America but the steel company also takes its place as one of the lowest cost producers in the world.During the third quarter, Bridgewater upped the ante by 110%, adding 2,134,146 shares of the company to the fund. This brings Bridgewater’s total CLF holding to 4,081,690 shares, valued at $29.5 million.Recently, steel prices have been facing significant pressure. Tariffs as well as the high cost of raw-materials have led to price increases, while weakening U.S. industrial production has in turn caused demand for steel to drop. Nonetheless, the bulls are standing firmly behind CLF.B.Riley FBR analyst Lucas Pipes sees its briquetted iron (HBI) growth project, which should reach production in the first half of 2020, as well as its level of diversification as giving it a leg up. “We believe that Cliffs retains considerable upside in a stronger commodity price environment in addition to the diversification and strategic benefits of the HBI project,” he commented. As a result, the analyst kept his Buy rating but did adjust his price target from $13 to $12. This implies that there’s room for 51% upside potential. (To watch Pipes’ track record, click here)Like Pipes, Credit Suisse analyst Curt Woodworth reduced the price target from $12 to $10 following CLF’s third quarter earnings results while remaining bullish overall. Even though he acknowledges that “the move lower in pellet premiums and HRC as well as mix shifts (less export) have conspired to lower the ASP outlook for CLF”, he believes that demand for HBI could be a major profit driver. He adds, “We believe the Street is too negative on CLF given optionality to benefit from new EAF production…CLF remains a best-in-class mining asset with significant FCF potential over the cycle.” (To watch Woodworth’s track record, click here)In general, the rest of the Street is in agreement. 6 Buys and 2 Holds assigned in the last three months add up to a ‘Strong Buy’ consensus. In addition, its $9.66 average price target suggests 21% upside potential. (See Cleveland-Cliffs stock analysis on TipRanks)Alexion Pharmaceuticals (ALXN) Alexion is a biopharma company trying to improve the lives of patients with rare disease including paroxysmal nocturnal hemoglobinuria (PNH), generalized Myasthenia Gravis (gMG), atypical hemolytic uremic syndrome (aHUS) as well as several others.Despite its impressive performance in its most recent quarter in terms of its financial results and solid execution commercially, shares have been weighed down by concerns over its C5 inhibitor franchise. Alexion is gearing up to face competition from biosimilar products currently in Phase 3 development. On top of this, Roche’s Japanese subsidiary, Chugai Pharmaceutical, filed a patent infringement suit against Alexion.To this end, the Street is keeping a close watch on ALXN following Dalio’s purchase. The billionaire’s fund snapped up 445,246 shares during the third quarter, bringing Bridgewater’s total ALXN stake to 475,487 shares, up a whopping 1473% from the previous quarter.Piper Jaffray analyst Christopher Raymond reminds investors that there are still big potential gains in store for ALXN in 2020. “As impressive commercial performance and pipeline development have continued, and with what we view as an increasingly credible defensive strategy to protect against biosimilar competition, we continue to like the setup on this name,” he explained. This prompted the five-star analyst to keep an Overweight rating and $180 price target. At this target, shares could climb 62% higher over the next twelve months. (To watch Raymond’s track record, click here)Similarly, other analysts have high hopes for the biopharma. With 18 Buys and 2 Holds given over the last three months, the consensus is that ALXN is a ‘Strong Buy’. Not to mention there’s 35% upside potential based on the $151 average price target. (See Alexion stock analysis on TipRanks)EQT Corporation (EQT)EQT is the largest natural gas producer in the U.S. with its asset base located in the heart of the Appalachian Basin. With shares down 52% year-to-date, investors are watching this name following Dalio’s decision to increase the fund’s holding.Dalio just added an additional 1,177,026 shares to the fund, bumping up the stake by 88% from the previous quarter. The holding’s value is now at $26.9 million, based on its total stake of 2,529,370 shares.It should be noted that several of the Street’s analysts highlight the fact the EQT is taking steps in the right direction. The management team has been using technology in order to improve its logistic and operational processes. RBC Capital analyst Scott Hanold argues this should “enable EQT to reduce well costs toward $730/lateral foot from the historical $970/foot.”On top of this, the company is potentially selling its Equitrans Midstream ownership within the next nine months, lending itself to Hanold’s conclusion that there will be a $0.10-0.15/Mcfe reduction for EQT. The analyst adds, “EQT shares are currently trading at just 4.4x our 2020 EBITDA, a slight discount to peers, despite having an FCF yield that could reach 10+%. We acknowledge the risk of a few bumps in the road with the new strategies, but the new team appears positioned to execute at EQT’s scale.”To this end, the analyst boosted the rating to Outperform and increased the price target from $16 to $17. This conveys his confidence in EQT’s ability to soar 88% over the next twelve months. (To watch Hanold’s track record, click here)Most analysts back Hanold's confident take on the gas giant, as TipRanks analytics showcase EQT as a Strong Buy. Based on 4 analysts polled by TipRanks in the last 3 months, 3 rate a Buy on the stock stock while one says "hold." The 12-month average price target stands at $14.00, marking a nearly 60% upside from where the stock is currently trading. (See EQT stock analysis on TipRanks)

  • Alexion Gets Approval for Label Expansion of Soliris in Japan
    Zacks

    Alexion Gets Approval for Label Expansion of Soliris in Japan

    Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.

  • Alexion (ALXN) Up 3.3% Since Last Earnings Report: Can It Continue?
    Zacks

    Alexion (ALXN) Up 3.3% Since Last Earnings Report: Can It Continue?

    Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire

    SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the prevention of relapse in patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica. “We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredictable disease,” said John Orloff, M.D., Executive Vice President and Head of Research and Development at Alexion.

  • Alexion Pharmaceuticals Does Not Look Boston Strong
    TheStreet.com

    Alexion Pharmaceuticals Does Not Look Boston Strong

    The Lightning Round is a very popular segment of Jim Cramer's Mad Money program. In the daily bar chart of ALXN, below, we can see that the prices were in a declining phase from April to September/October. The daily On-Balance-Volume (OBV) line has been weak from July and tells us that sellers of ALXN have been more aggressive -- this is not what chart watchers want to see.

  • Biogen, Novartis named in settlement between foundation, federal prosecutors
    American City Business Journals

    Biogen, Novartis named in settlement between foundation, federal prosecutors

    A Florida-based foundation is paying $4 million to settle claims it worked with two of the Boston area’s biggest drugmakers to use kickback payments to boost sales of their drugs.

  • The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals
    Zacks

    The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals

    The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals

  • Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
    Zacks

    Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH

    Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.